Evidence map›Paper›PMID 29025958›Full record

ArticleMolecular cancer research : MCR2018

miR-34a Regulates Expression of the Stathmin-1 Oncoprotein and Prostate Cancer Progression.

Balabhadrapatruni V S K Chakravarthi, Darshan S Chandrashekar, Sumit Agarwal, Sai Akshaya Hodigere Balasubramanya, Satya S Pathi, Moloy T Goswami, Xiaojun Jing, Rui Wang, Rohit Mehra, Irfan A Asangani and 6 more

Erratum issuedOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular cancer research : MCR, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 61 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

Balabhadrapatruni V S K ChakravarthiDepartment of Pathology, University of Alabama at Birmingham, Birmingham, Alabama.
Darshan S ChandrashekarDepartment of Pathology, University of Alabama at Birmingham, Birmingham, Alabama.
Sumit AgarwalDepartment of Pathology, University of Alabama at Birmingham, Birmingham, Alabama.
Sai Akshaya Hodigere BalasubramanyaDepartment of Pathology, University of Alabama at Birmingham, Birmingham, Alabama.
Satya S PathiMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.
Moloy T GoswamiMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.
Xiaojun JingMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.
Rui WangMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.
Rohit MehraMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.
Irfan A AsanganiMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.
Arul M ChinnaiyanMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.
Upender ManneDepartment of Pathology, University of Alabama at Birmingham, Birmingham, Alabama.
Guru SonpavdeDepartment of Medical Oncology, GU section, Dana-Farber Cancer Institute, Boston, Massachusetts.
George J NettoDepartment of Pathology, University of Alabama at Birmingham, Birmingham, Alabama.
Jennifer GordetskyDepartment of Pathology, University of Alabama at Birmingham, Birmingham, Alabama.
Sooryanarayana VaramballyDepartment of Pathology, University of Alabama at Birmingham, Birmingham, Alabama. svarambally@uabmc.edu.
University of Alabama at Birmingham · USMichigan Center for Translational Pathology · USDana-Farber Cancer Institute · USMichigan Medicine · USUniversity of Michigan · US

Funding

Regulation of Polycomb Repressive Complex 1 by EZH2 Regulated microRNAs in CancerR01CA157845 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI VARAMBALLY, SOORYANARAYANA · 2011 to 2015
$1.6M
Role of Transcriptional Corepressor CtBP1 in Prostate Cancer ProgressionR01CA154980 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI VARAMBALLY, SOORYANARAYANA · 2012 to 2016
$1.5M
Howard Hughes Medical InstituteNCI NIH HHS R01 CA154980NCI NIH HHS R01 CA157845
6 · The paper itself

Abstract

In aggressive prostate cancers, the oncoprotein STMN1 (also known as stathmin 1 and oncoprotein 18) is often overexpressed. STMN1 is involved in various cellular processes, including cell proliferation, motility, and tumor metastasis. Here, it was found that the expression of STMN1 RNA and protein is elevated in metastatic prostate cancers. Knockdown of STMN1 resulted in reduced proliferation and invasion of cells and tumor growth and metastasis

Indexed as

Alcohol OxidoreductasesAnimalsCell Line, TumorCell MovementCell ProliferationDisease ProgressionDNA-Binding ProteinsGene Expression Regulation, NeoplasticGrowth Differentiation Factor 15HumansMaleMiceMicroRNAsProstateProstatic NeoplasmsStathminAlcohol OxidoreductasesC-terminal binding proteinDNA-Binding ProteinsGDF15 protein, humanGrowth Differentiation Factor 15MicroRNAsMIRN34 microRNA, humanStathminSTMN1 protein, human

Identifiers

PMID29025958
PMCPMC5897228
OpenAlexW2762769581

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.